Pliant: Enrollment for Phase 2a bexotegrast trial has commenced following review

Pliant Therapeutics announced that, following an independent Data Safety Monitoring Board safety review, enrollment has commenced in a Phase 2a trial of bexotegrast at 320 mg dosed once daily for at least 24 weeks and up to 48 weeks in patients with primary sclerosing cholangitis. Bexotegrast, is an oral, small molecule, dual-selective inhibitor of alphavbeta6 and alphavbeta1 integrins being developed for the treatment of PSC and idiopathic pulmonary fibrosis. Bexotegrast has been administered to over 600 study participants to date, including healthy volunteers and patients, with no drug-related severe or serious adverse events reported to date. "We are pleased to see the continued favorable safety and tolerability profile exhibited by bexotegrast, allowing us to evaluate a higher dose at a longer treatment duration in patients with PSC," said Eric Lefebvre M.D. Chief Medical Officer of Pliant Therapeutics. "We recognize the high unmet medical need in PSC, as there are no FDA approved therapies for the indication and look forward to sharing 12-week interim data from our Phase 2a trial in the third quarter."